The U.S. Food and Drug Administration has approved the first weight loss treatment device, the Maestro Rechargeable System by EnteroMedics of St. Paul, Minnesota.
Combo Zerbaxa is sanctioned for complicated intra-abdominal and urinary tract infections
Targeted pathogens include AIDS-causing HIV, hepatitis B and C, and the West Nile virus
NBI visualized non-muscle-invasive bladder cancer lesions in 17% more patients and 24% more tumors than white light.
Once-weekly subcutaneous injection of Trulicity (dulaglutide), a glucagon-like peptide-1 receptor agonist.
Blocks reabsorption of glucose by kidneys.
The product is self-administered via a nasal applicator.
FDA clears albiglutide as an adjunct to diet and exercise for glycemic control in adult type 2 diabetes patients.
Astellus Pharma and Medivation ask the FDA to approve enzalutamide as a treatment for advanced prostate cancer in chemotherapy-naïve men.
However, device doesn't perform as well in children as in adults, FDA says.
Agency pointed to recent studies citing possible heightened heart risk tied to the treatments.
To be used along with proper diet and exercise.
Not all experts are happy with granting wider access to the troubled medication, however.
UroLift system, a permanent implant, helps relieve blocked urine flow.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)